Loading...

Bellicum Pharmaceuticals

DB:BPX
Snowflake Description

Adequate balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BPX
DB
$136M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
  • Bellicum Pharmaceuticals has significant price volatility in the past 3 months.
BPX Share Price and Events
7 Day Returns
-11.3%
DB:BPX
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-55.1%
DB:BPX
-10.2%
DE Biotechs
-6%
DE Market
BPX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Bellicum Pharmaceuticals (BPX) -11.3% -16.2% -4.4% -55.1% -72.1% -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • BPX underperformed the Biotechs industry which returned -10.2% over the past year.
  • BPX underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
BPX
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Bellicum Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Bellicum Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Bellicum Pharmaceuticals.

DB:BPX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:BPX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (26.52%))
1.503
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.5
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.503 * 5.96%)
9.19%

Discounted Cash Flow Calculation for DB:BPX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Bellicum Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:BPX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.19%)
2019 -85.00 Analyst x1 -77.85
2020 -91.10 Analyst x1 -76.41
2021 -60.10 Analyst x1 -46.17
2022 -28.60 Analyst x1 -20.12
2023 29.10 Analyst x1 18.75
2024 44.42 Est @ 52.66% 26.22
2025 60.83 Est @ 36.93% 32.88
2026 76.60 Est @ 25.92% 37.92
2027 90.54 Est @ 18.21% 41.05
2028 102.15 Est @ 12.82% 42.42
Present value of next 10 years cash flows $-21.32
DB:BPX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $102.15 × (1 + 0.23%) ÷ (9.19% – 0.23%)
$1,142.81
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,142.81 ÷ (1 + 9.19%)10
$474.54
DB:BPX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-21.32 + $474.54
$453.22
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $453.22 / 44.32
$10.23
DB:BPX Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:BPX represents 0.90948x of NasdaqGM:BLCM
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.90948x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 10.23 x 0.90948
€9.30
Value per share (EUR) From above. €9.30
Current discount Discount to share price of €2.78
= -1 x (€2.78 - €9.30) / €9.30
70.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Bellicum Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is €2.78 vs Future cash flow value of €9.3
Current Discount Checks
For Bellicum Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Bellicum Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Bellicum Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Bellicum Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Bellicum Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:BPX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.44
NasdaqGM:BLCM Share Price ** NasdaqGM (2019-04-18) in USD $3.06
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Bellicum Pharmaceuticals.

DB:BPX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:BLCM Share Price ÷ EPS (both in USD)

= 3.06 ÷ -2.44

-1.26x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bellicum Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Bellicum Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Bellicum Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:BPX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.26x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
18.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Bellicum Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Bellicum Pharmaceuticals's assets?
Raw Data
DB:BPX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.57
NasdaqGM:BLCM Share Price * NasdaqGM (2019-04-18) in USD $3.06
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:BPX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:BLCM Share Price ÷ Book Value per Share (both in USD)

= 3.06 ÷ 1.57

1.95x

* Primary Listing of Bellicum Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bellicum Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Bellicum Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Bellicum Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Bellicum Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
18.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Bellicum Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Bellicum Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Bellicum Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Bellicum Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:BPX Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:BPX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 18.6%
DB:BPX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 57.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:BPX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:BPX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 185 -7 2
2022-12-31 112 -56 3
2021-12-31 46 -103 3
2020-12-31 4 -123 3
2019-12-31 1 -112 3
DB:BPX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -75 -98
2018-09-30 1 -67 -93
2018-06-30 1 -68 -92
2018-03-31 0 -69 -93
2017-12-31 0 -73 -92
2017-09-30 0 -75 -90
2017-06-30 0 -69 -84
2017-03-31 0 -62 -76
2016-12-31 0 -50 -69
2016-09-30 0 -48 -66
2016-06-30 0 -44 -62
2016-03-31 0 -40 -56

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Bellicum Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Bellicum Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:BPX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Bellicum Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BPX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.11 0.17 -0.39 2.00
2022-12-31 -0.93 -0.35 -1.58 3.00
2021-12-31 -1.69 -1.36 -2.27 3.00
2020-12-31 -1.98 -1.40 -2.43 4.00
2019-12-31 -2.15 -1.60 -2.66 5.00
DB:BPX Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.44
2018-09-30 -2.46
2018-06-30 -2.63
2018-03-31 -2.79
2017-12-31 -2.89
2017-09-30 -2.98
2017-06-30 -2.94
2017-03-31 -2.81
2016-12-31 -2.57
2016-09-30 -2.47
2016-06-30 -2.32
2016-03-31 -2.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Bellicum Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Bellicum Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Bellicum Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Bellicum Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Bellicum Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Bellicum Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Bellicum Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Bellicum Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Bellicum Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Bellicum Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BPX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.12 -98.04 25.00
2018-09-30 0.74 -92.73 23.08
2018-06-30 0.57 -92.36 20.69
2018-03-31 0.21 -92.65 20.81
2017-12-31 0.19 -91.78 21.05
2017-09-30 0.34 -89.80 20.20
2017-06-30 0.32 -84.09 19.88
2017-03-31 0.42 -76.14 18.57
2016-12-31 0.39 -69.24 16.93
2016-09-30 0.34 -66.15 16.53
2016-06-30 0.28 -61.84 16.16
2016-03-31 0.27 -55.87 14.76
2015-12-31 0.28 -48.55 12.67
2015-09-30 0.26 -106.00 10.86
2015-06-30 0.87 -97.01 8.28
2015-03-31 1.34 -90.33 6.09
2014-12-31 1.78 -85.40 4.34
2014-09-30 2.58 -13.99 3.15
2014-06-30 2.65 -11.78 2.51
2014-03-31 2.29 -9.91 2.59
2013-12-31 1.94 -9.06 1.96
2012-12-31 1.47 -7.02 1.94

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Bellicum Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Bellicum Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Bellicum Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Bellicum Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Bellicum Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Bellicum Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Bellicum Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Bellicum Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Bellicum Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Bellicum Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Bellicum Pharmaceuticals Company Filings, last reported 3 months ago.

DB:BPX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 68.48 35.96 93.00
2018-09-30 92.46 35.75 112.75
2018-06-30 112.54 35.54 129.38
2018-03-31 66.18 35.32 82.11
2017-12-31 84.65 35.11 98.90
2017-09-30 103.12 30.92 113.08
2017-06-30 122.71 30.70 130.23
2017-03-31 143.12 30.47 147.56
2016-12-31 96.57 20.39 103.77
2016-09-30 113.09 20.23 105.31
2016-06-30 127.49 15.11 105.57
2016-03-31 140.37 14.98 108.27
2015-12-31 152.02 0.13 94.06
2015-09-30 166.11 0.00 113.23
2015-06-30 177.01 0.00 119.30
2015-03-31 185.36 0.00 183.64
2014-12-31 191.64 0.00 191.60
2014-09-30 179.01 35.66 213.47
2014-06-30 13.88 0.60 12.16
2014-03-31 11.77 0.80 11.17
2013-12-31 11.77 0.80 11.17
2012-12-31 2.18 0.45 1.63
  • Bellicum Pharmaceuticals's level of debt (52.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (6.8% vs 52.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Bellicum Pharmaceuticals has sufficient cash runway for 1.2 years based on current free cash flow.
  • Bellicum Pharmaceuticals has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 18.6% each year.
X
Financial health checks
We assess Bellicum Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Bellicum Pharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Bellicum Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Bellicum Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Bellicum Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Bellicum Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Bellicum Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:BPX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:BPX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Bellicum Pharmaceuticals has not reported any payouts.
  • Unable to verify if Bellicum Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Bellicum Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Bellicum Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Bellicum Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Bellicum Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Bellicum Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Bellicum Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Bellicum Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rick Fair
COMPENSATION $4,927,464
AGE 49
TENURE AS CEO 2.3 years
CEO Bio

Mr. Richard A. Fair, also known as Rick, serves as Director of Clovis Oncology, Inc since October 11, 2018.served as Chief Executive Officer and President of Bellicum Pharmaceuticals, Inc. since January 31, 2017. Mr. Fair served as Head of Oncology Global Product Strategy and Senior Vice President at Genentech, Inc. until January 31, 2017. Mr. Fair served as Senior Vice President, Therapeutic Head Oncology Global Product Strategy at Genentech, Inc., a subsidiary of Roche Holding AG. He served as Vice President of Sales and Marketing for Targeted Small Molecule Franchise at Genentech, Inc. Mr. Fair led oncology product strategy and global commercialization, overseeing the launch of five new molecular entities, including TECENTRIQ®, the first immunotherapy approval for patients with advanced bladder cancer and numerous line extensions. He also contributed to a substantial expansion of investment into cancer immunotherapy and precision medicine. Previously, he held several commercial leadership positions within Genentech, including franchise leadership with P&L responsibility for its thrombolytics and oral oncolytics businesses. Mr. Fair served as Senior Vice President, Therapeutic Head Oncology Global Product Strategy at Genentech, Inc., a subsidiary of Roche Holding AG. Prior to Genentech, Mr. Fair spent nine years in the pharmaceutical business at Johnson & Johnson, holding leadership roles in marketing, managed care and reimbursement strategy and managed care customer management. He has been Director of Bellicum Pharmaceuticals, Inc. since January 31, 2017. Mr. Fair holds a Bachelor of Science from the University of Michigan and a Masters of Business Administration from Columbia Business School.

CEO Compensation
  • Insufficient data for Rick to compare compensation growth.
  • Rick's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Bellicum Pharmaceuticals management team in years:

1.2
Average Tenure
49
Average Age
  • The average tenure for the Bellicum Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Rick Fair

TITLE
President
COMPENSATION
$5M
AGE
49
TENURE
2.3 yrs

Alan Smith

TITLE
Executive Vice President of Technical Operations
COMPENSATION
$1M
AGE
60
TENURE
3.5 yrs

Tom Farrell

TITLE
Consultant
COMPENSATION
$2M
AGE
55
TENURE
2.3 yrs

Atabak Mokari

TITLE
Chief Financial Officer
AGE
41
TENURE
0.3 yrs

Rosie Williams

TITLE
Interim Principal Accounting Officer
TENURE
0.7 yrs

Shane Ward

TITLE
General Counsel & Corporate Secretary
AGE
43
TENURE
0.9 yrs

Aaron Foster

TITLE
Head of Research & Senior VP
TENURE
0.2 yrs

Greg Naeve

TITLE
Chief Business Officer
AGE
53
TENURE
1.7 yrs

Bill Grossman

TITLE
Chief Medical Officer
AGE
48
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the Bellicum Pharmaceuticals board of directors in years:

2.6
Average Tenure
56
Average Age
  • The average tenure for the Bellicum Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

James Brown

TITLE
Chairman of the Board
COMPENSATION
$148K
AGE
53
TENURE
4.3 yrs

Rick Fair

TITLE
President
COMPENSATION
$5M
AGE
49
TENURE
2.3 yrs

Reid Huber

TITLE
Director
COMPENSATION
$129K
AGE
46
TENURE
4.5 yrs

Jon Stonehouse

TITLE
Director
COMPENSATION
$133K
AGE
57
TENURE
4.3 yrs

Steve Davis

TITLE
Director
COMPENSATION
$129K
AGE
57
TENURE
3.8 yrs

David Spencer

TITLE
Scientific & Clinical Advisory Board
AGE
56
TENURE
0.1 yrs

Jim Daly

TITLE
Director
COMPENSATION
$107K
AGE
56
TENURE
2.9 yrs

Ed Harrigan

TITLE
Director
AGE
65
TENURE
1.2 yrs

Judith Klimovsky

TITLE
Director
AGE
60
TENURE
0.3 yrs

Malcom Brenner

TITLE
Scientific & Clinical Advisory Board
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
13. Nov 18 Buy Jon Stonehouse Individual 09. Nov 18 09. Nov 18 10,000 €4.02 €40,210
X
Management checks
We assess Bellicum Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Bellicum Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesù, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.

Details
Name: Bellicum Pharmaceuticals, Inc.
BPX
Exchange: DB
Founded: 2004
$120,594,113
44,320,559
Website: http://www.bellicum.com
Address: Bellicum Pharmaceuticals, Inc.
2130 West Holcombe Boulevard,
Suite 800,
Houston,
Texas, 77030,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM BLCM Common Stock Nasdaq Global Market US USD 18. Dec 2014
DB BPX Common Stock Deutsche Boerse AG DE EUR 18. Dec 2014
LSE 0HMS Common Stock London Stock Exchange GB USD 18. Dec 2014
Number of employees
Current staff
Staff numbers
173
Bellicum Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:46
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/19
Last earnings filing: 2019/03/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.